The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Calikusu, Zuleyha ^a   Yildirim, Yesim ^b   Akcali, Zafer ^c   Sakalli, Hakan ^c   Bal, Nebil ^c   Unal, Ilker ^d   Ozyilkan, Ozgur ^c  

^a Acibadem Maslak Hospital   (Turkey)

^b Sivas Numune Hastanesi   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

^d CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; NAVELBINE; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 68749105999     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-97     Document Type: Article

References (24)

1. Cancer statistics. RT Greenlee MB Hill-Harmon T Murray M Thun, CA Cancer J Clin 2001 51 15 36 10.3322/canjclin.51.1.15 11577478
2. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson, NEJM 2006 14;355 24 2542 50 10.1056/NEJMoa061884 (Pubitemid 44917502)
3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson Eastern Cooperative Oncology Group, N Engl J Med 2002 346 92 98 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
4. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. K Kelly J Crowley PA Bunn Jr CA Presant PK Grevstad CM Moinpour SD Ramsey AJ Wozniak GR Weiss DF Moore, J Clin Oncol 2001 19 3210 3218 11432888 (Pubitemid 32591438)
5. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. F Fossella JR Pereira JV Pawel A Pluzanska V Gorbounova E Kaukel KV Mattson R Ramlau A Szczesna P Fidias, J Clin Oncol. 2004 21 16 3016 3024 10.1200/JCO.2003.12.046
6. Correlation of intrinsic chemoresistance of nonsmall cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutation. CM Tsai KT Chang RP Perng T Mitsudomi MH Chen C Kadoyama AF Gazdar, J NCI 1993 85 897 901 (Pubitemid 23157130)
7. Apoptozis and chemotherapy resistance. JA Hickman, Eur J Cancer 1996 32A 921 6 10.1016/0959-8049(96)00080-9 8763333 (Pubitemid 26191760)
8. National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer. FA Shepherd J Rodrigues Pereira T Ciuleanu EH Tan V Hirsh S Thongprasert D Campos S Maoleekoonpiroj M Smylie R Martins, N Engl J Med 2005 353 123 132 10.1056/NEJMoa050753 16014882 (Pubitemid 41058344)
9. Randomized Phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial E4599. AB Sandler R Gray J Brahmer A Dowlati JH Schiller MC Perry DH Johnson, Proc Am Soc Clin Oncol 2005 23 A4
10. Basic science of HER-2/neu: a review. M-C Hung Y-K Lau, Semin Oncol 1999 26 51 9 10482194
11. Similary of protein encoded by the human c-erbB2 gene to epidermal growth factor receptor. T Jammato S Ikava T Akiyama K Semba, Nature 1986 319 230 4 10.1038/319230a0 3003577 (Pubitemid 16128786)
12. The erb-B signaling network: receptor heterodimerization in development and cancer. MA Olagione RM Meve HA Lane NE Hynes, EMBO J 2000 19 3159 67 10880430 10.1093/emboj/19.13.3159
13. Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8. Z Akcali Z Calikusu H Sakalli O Ozyilkan, Tumori 2008 94 4 474 80 18822681
14. Her2/neu expression in malignant lung tumors. FR Hirsch WA Franklin R Veve M Varella-Garcia PA Bunn, Semin Oncol. 2002 29 1 Suppl 4 51 58 10.1053/sonc.2002.31523 11894014 (Pubitemid 34226519)
15. Synchronous overexpression of epidermal growth factor receptor and HER2/neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer patients. A Onn AM Correa M Gilcrease T Isobe E Massarelli CD Bucana MS O'Reilly WK Hong IJ Fidler JB Putnam, Clin Cancer Res 2004 10 136 143 10.1158/1078-0432.CCR-0373-3 14734462 (Pubitemid 38114172)
16. P53 and Her2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. J Fijolek E Wiatr E Rowinska-Zakrewska D Giedronowicz R Langfort M Chabowski T Orlowski K Roszkowski, Int J Biol Markers 2006 21 81 87 16847810 (Pubitemid 44210036)
17. Her2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. K Junker U Stachetzki D Rademacher A Linder HN Macha A Heinecke KM Müller M Thomas, Lung Cancer 1998 22 181 190 10.1016/S0169-5002(98)00086-5 10048471 (Pubitemid 29067392)
18. Trastuzumab in the treatment of non-small cell lung cancer. GH Azoli LM Krug VA Miller MG Kris R Mass, Seminars in Oncol 2002 29 suppl 4 59 65 10.1053/sonc.2002.31526 (Pubitemid 34226520)
19. Association of Her-2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysis. H Nakamura N Kawasaki M Taguchi K Kabasawa, Cancer 2005 103 1865 1873 10.1002/cncr.20957 15770690 (Pubitemid 40563259)
20. Her-2/neu in node negative breast cancer: prognostic significance of overexpression Influenced by presence of in situ carcinoma. DC Allred GM Clark AK Tandon CD Tormey CK Osborne WL McGuire, J Clin Oncol 1992 10 599 605 1548522
21. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer. DJ Slamon B Leyland-Jones S Sahk H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram, N Engl J Med 2001 344 783 792 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
22. Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. G Pauletti S Dandekar H Rong L Ramos H Peng R Seshadri DJ Slamon, J Clin Oncol 2000 18 3651 3664 11054438 (Pubitemid 30816223)
23. Evaluation of HER2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH). F Hirsch R Veve M Varella-Garcia PA Bunn WA Franklin, Proc Am Soc Clin Oncol 2000 19 486a (abstr 1900)
24. Impact of Her2 gene and protein status on the treatment outcome of cisplatin-based chemotherapy for locally advanced nonsmall cell lung cancer. S Kuyama K Hotta M Tabata Y Segawa Y Fujiwara N Takigawa K Kiura H Ueoka K Eguchi M Tanimoto, J Thorac Oncol. 2008 3 5 477 481 18448999 (Pubitemid 351630274)